busulfan indications/contra

Stem definitionDrug idCAS RN
antineoplastic, alkylating agents, methanesulfonates 438 55-98-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • busilvex
  • busulfan
  • busulfex
  • busulphan
  • citosulfan
  • glyzophrol
  • leucosulfan
  • sulphabutin
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
  • Molecular weight: 246.29
  • Formula: C6H14O6S2
  • CLOGP: -0.59
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 86.74
  • ALOGS: -1.68
  • ROTB: 7

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
June 26, 1954 FDA ASPEN GLOBAL

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute graft versus host disease 1896.03 102.06 316 3480 1486 3380577
Graft versus host disease 1587.49 102.06 286 3510 2261 3379802
Venoocclusive liver disease 1487.95 102.06 247 3549 1115 3380948
Chronic graft versus host disease 1338.03 102.06 221 3575 957 3381106
Venoocclusive disease 1043.78 102.06 164 3632 472 3381591
Acute graft versus host disease in skin 923.97 102.06 155 3641 744 3381319
Mucosal inflammation 854.53 102.06 209 3587 7774 3374289
Cytomegalovirus infection 849.71 102.06 187 3609 4320 3377743
Cystitis haemorrhagic 583.16 102.06 108 3688 984 3381079
Febrile neutropenia 501.82 102.06 167 3629 18808 3363255
Sepsis 456.87 102.06 179 3617 32194 3349869
Acute graft versus host disease in intestine 445.17 102.06 77 3719 452 3381611
Multiple organ dysfunction syndrome 393.17 102.06 130 3666 14280 3367783
Infection 377.52 102.06 146 3650 25256 3356807
Drug administration error 376.57 102.06 104 3692 6172 3375891
Off label use 368.81 102.06 179 3617 53798 3328265
Acute myeloid leukaemia recurrent 343.94 102.06 60 3736 372 3381691
Leukaemia recurrent 326.29 102.06 60 3736 520 3381543
Transplant failure 324.41 102.06 61 3735 604 3381459
Stomatitis 323.36 102.06 107 3689 11745 3370318
Thrombotic microangiopathy 282.99 102.06 67 3729 2125 3379938
Cytomegalovirus viraemia 279.52 102.06 55 3741 704 3381359
Meningitis tuberculous 271.69 102.06 44 3752 159 3381904
Blood follicle stimulating hormone increased 268.43 102.06 42 3754 114 3381949
BK virus infection 259.90 102.06 49 3747 492 3381571
Respiratory failure 250.26 102.06 106 3690 23035 3359028
Graft versus host disease in skin 249.93 102.06 46 3750 400 3381663
Thrombocytopenia 237.21 102.06 116 3680 35152 3346911
Primary hypogonadism 236.14 102.06 35 3761 56 3382007
Acute myeloid leukaemia 234.71 102.06 69 3727 5104 3376959

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01AB01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Alkyl sulfonates
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000477 Alkylating Agents
CHEBI has role CHEBI:67105 insect sterilant
CHEBI has role CHEBI:35610 antineoplastic agent
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D019653 Myeloablative Agonists
MeSH PA D009676 Noxae

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Allogeneic bone marrow transplantation indication 58390007
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Mycosis contraindication 3218000 DOID:1564
Fanconi's anemia contraindication 30575002 DOID:13636
Viral disease contraindication 34014006 DOID:934
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Fibrosis of lung contraindication 51615001 DOID:3770
Portal vein obstruction contraindication 57348003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Bacterial infectious disease contraindication 87628006 DOID:104
Radiation oncology AND/OR radiotherapy contraindication 108290001
Hypomagnesemia contraindication 190855004
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001
Severe Bone Marrow Depression contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Matrix metalloproteinase-9 Enzyme IC50 5.28 DRUG MATRIX
DNA DNA OTHER DRUG LABEL DRUG LABEL

External reference:

scroll-->
IDSource
4018773 VUID
N0000147076 NUI
C0006463 UMLSCUI
7136 IUPHAR_LIGAND_ID
D00248 KEGG_DRUG
DB01008 DRUGBANK_ID
CHEMBL820 ChEMBL_ID
2478 PUBCHEM_CID
4018773 VANDF
N0000007483 NDFRT
N0000147076 NDFRT
002638 NDDF
1828 RXNORM
2571007 SNOMEDCT_US
387138002 SNOMEDCT_US
4309 MMSL
d00183 MMSL
121305 MMSL
CHEBI:28901 CHEBI
D002066 MESH_DESCRIPTOR_UI
G1LN9045DK UNII
564 INN_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
N/A HUMAN PRESCRIPTION DRUG LABEL 1 0517-0920 INJECTION 6 mg INTRAVENOUS ANDA 18 sections
Busulfan HUMAN PRESCRIPTION DRUG LABEL 1 25021-241 INJECTION, SOLUTION, CONCENTRATE 6 mg INTRAVENOUS ANDA 18 sections
Busulfan HUMAN PRESCRIPTION DRUG LABEL 1 45963-640 INJECTION, SOLUTION, CONCENTRATE 6 mg INTRAVENOUS ANDA 18 sections
Busulfan HUMAN PRESCRIPTION DRUG LABEL 1 51817-170 INJECTION 6 mg INTRAVENOUS ANDA 18 sections
BUSULFEX HUMAN PRESCRIPTION DRUG LABEL 1 59148-047 INJECTION 6 mg INTRAVENOUS NDA 18 sections
BUSULFEX HUMAN PRESCRIPTION DRUG LABEL 1 59148-070 INJECTION 6 mg INTRAVENOUS NDA 19 sections
Busulfan HUMAN PRESCRIPTION DRUG LABEL 1 67457-893 INJECTION 6 mg INTRAVENOUS ANDA 18 sections
Busulfan HUMAN PRESCRIPTION DRUG LABEL 1 70121-1244 INJECTION 6 mg INTRAVENOUS ANDA 18 sections
MYLERAN HUMAN PRESCRIPTION DRUG LABEL 1 76388-713 TABLET, FILM COATED 2 mg ORAL NDA 14 sections